eTheRNA immunotherapies plans to advance ECI-006 to a Phase I/II trial in the third quarter of this year following positive first-in-human data showing immune response in 35% of patients in an adjuvant setting . . .
eTheRNA Advances mRNA-Based Melanoma Immunotherapy ECI-006
